慢加急性肝衰竭分级与特利加压素联合白蛋白治疗肝肾综合征应答的关联
该回顾性分析纳入欧洲4个队列共298例1型肝肾综合征患者,发现慢加急性肝衰竭(ACLF)1级、2级、3级患者对特利加压素联合白蛋白治疗的应答率分别为60%、48%、29%(P<.001),ACLF分级是治疗应答的最大决定因素,且独立于治疗应答影响90天生存。
要点
- 1型肝肾综合征患者中,ACLF 1级应答率60%,2级48%,3级29%。
- ACLF分级是特利加压素联合白蛋白治疗应答的最大决定因素。
- ACLF分级独立于治疗应答影响90天死亡率。
核心结论
- 在1型肝肾综合征患者中,ACLF分级是特利加压素联合白蛋白治疗应答的最大决定因素。
- ACLF分级独立于治疗应答影响生存,作者认为应为合并肾外器官衰竭的1型肝肾综合征患者开发新的治疗策略。
研究设计与样本
- 回顾性分析2007年2月至2016年1月欧洲医疗中心4个连续1型肝肾综合征患者队列,共298例,均接受特利加压素联合白蛋白治疗。
- 收集治疗前和治疗期间的人口学、临床和实验室数据,随访至死亡、肝移植或肝肾综合征诊断后90天。
主要发现
- 53%的患者对治疗有应答。
- ACLF 1级患者中60%有应答,ACLF 2级患者中48%有应答,ACLF 3级患者中29%有应答(P<.001)。
- 多变量分析中,基线血清肌酐水平(比值比0.23;P=.001)和ACLF分级(比值比0.63;P=.01)与治疗应答独立相关。
- 患者年龄(风险比[HR]1.05;P<.001)、白细胞计数(HR 1.51;P=.006)、ACLF分级(HR 2.06;P<.001)和治疗无应答(HR 0.41;P<.001)与90天死亡率相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Type 1 hepatorenal syndrome (HRS) is the most high-risk type of renal failure in patients with cirrhosis. Terlipressin and albumin are effective treatments for type 1 HRS. However, the effects of acute on chronic liver failure (ACLF) grade on response to treatment are not clear. We aimed to identify factors associated with response to treatment with terlipressin and albumin in patients with type 1 HRS (reduction in serum level of creatinine to below 1.5 mg/dL at the end of treatment) and factors associated with death within 90 days of HRS diagnosis (90-day mortality). METHODS: We performed a retrospective analysis of 4 different cohorts of consecutive patients with HRS treated with terlipressin and albumin from February 2007 through January 2016 at medical centers in Europe (total, 298 patients). We analyzed demographic, clinical, and laboratory data collected before and during treatment; patients were followed until death, liver transplantation, or 90 days after HRS diagnosis. RESULTS: Response to treatment was observed in 53% of patients. Of patients with grade 1 ACLF, 60% responded to treatment; among those with grade 2 ACLF, 48% responded, and among those with grade 3 ACLF, 29% responded (P < .001 for comparison between grades). In multivariate analysis, baseline serum level of creatinine (odds ratio, 0.23; P = .001) and ACLF grade (odds ratio, 0.63; P = .01) were independently associated with response to treatment. Patient age (hazard ratio [HR], 1.05; P < .001), white blood cell count (HR, 1.51; P = .006), ACLF grade (HR, 2.06; P < .001), and no response to treatment (HR, 0.41; P < .001) associated with 90-day mortality. CONCLUSION: In a retrospective analysis of data from 4 cohorts of patients treated for type 1 HRS, we found ACLF grade to be the largest determinant of response to terlipressin and albumin. ACLF grade affects survival independently of response to treatment. New therapeutic strategies should be developed for patients with type 1 HRS and extrarenal organ failure.
引用
- Piano S, Schmidt HH, Ariza X, et al. Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome. Clin Gastroenterol Hepatol. 2018. PMID: 29391267. doi:10.1016/j.cgh.2018.01.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。